SFUNGA THERAPEUTICS
Sfunga Therapeutics is a research and development company that focuses on systemic and life-threatening fungal infections.
SFUNGA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical Therapeutics
Address:
Boston, Massachusetts, United States
Country:
United States
Status:
Active
Current Employees Featured
Founder
More informations about "Sfunga Therapeutics"
Elion Therapeutics - Crunchbase Company Profile
Organization. Elion Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Also Known As Sfunga …See details»
Elion Therapeutics loses $81 Million Series Funding Round Led by ...
NEW YORK, NY – (June 17, 2024) -- Elion Therapeutics (“Elion”, formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life-threatening invasive …See details»
Elion Therapeutics Closes $81 Million Series B Funding …
NEW YORK, June 17, 2024 /PRNewswire/ -- Elion Therapeutics ("Elion", formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life-threatening invasive ...See details»
Elion Therapeutics Closes $81 Million Series B Funding Round Led …
Jun 17, 2024 Elion Therapeutics ("Elion", formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life-threatening invasive fungal infections …See details»
Sfunga Therapeutics and Deerfield Management Announce …
Nov 8, 2023 Sfunga Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections using a novel approach rooted …See details»
尖端生物技术公司Elion Therapeutics完成8100万美元B轮融资， …
NEW YORK, June 17, 2024 /PRNewswire/ -- Elion Therapeutics ('Elion', formerly Sfunga Therapeutics), a biotechnology company dedicated to transforming the treatment of life …See details»
Sfunga Therapeutics and Deerfield Management Announce …
About Sfunga Sfunga Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections using a novel approach rooted …See details»
Sfunga Therapeutics and Deerfield Management Announce
Nov 8, 2023 Sfunga Therapeutics ("Sfunga"), a biotechnology company, and Deerfield Management Company ("Deerfield"), a healthcare investment firm, today announced the …See details»
Sfunga Therapeutics and Deerfield Management Announce …
Sfunga Therapeutics and Deerfield Management announce the publication of a novel antifungal SF001 in Nature.See details»
SFUNGA THERAPEUTICS, INC. Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for SFUNGA THERAPEUTICS, INC. of Champaign, IL. Get the latest business insights from Dun & Bradstreet.See details»
Elion nets $81M to fund development of antifungal with lower …
Jun 17, 2024 Elion – originally formed back in 2019 as Sfunga Therapeutics – says SF001 has been designed to mitigate these renal toxicities while maintaining potency through more …See details»
Elion Therapeutics raises funds to develop antifungal medication ...
Jun 21, 2024 Elion Therapeutics, formerly called Sfunga Therapeutics, is developing an intravenous drug to treat fungal infections among immunocompromised patients, including …See details»
Antifungal developer raises $81 million | C&EN Global Enterprise
Jun 24, 2024 Elion Therapeutics, which rebranded from Sfunga Therapeutics in November , has raised $81 million in a funding round co-led by Deerfield Management and the antimicrobial …See details»
New Antifungal Molecule Kills Fungi Without Toxicity - Veterinary ...
Nov 13, 2023 Sfunga Therapeutics also supported the work in part, and Burke received consulting income and equity in the company. The National Institutes of Health supported this …See details»
Sfunga Therapeutics - Headquarter Location, Corporate Office …
Sfunga Therapeutics is Drug Discovery in United States that focus on clinical research business. They cover business area such as provider, clinical research and development service, …See details»
Elion Therapeutics Closes $81 Million Series B Funding Round Led …
- Funds to support the advancement of SF001, a next-generation polyene antifungal designed for reduced toxicity. NEW YORK, June 17, 2024-- Elion Therapeutics ("Elion", formerly Sfunga …See details»
Designing a safer antifungal drug - National Institutes of Health …
Dec 5, 2023 AM-2-19 has been licensed to Sfunga Therapeutics and recently entered a phase 1 clinical trial. —by Sharon Reynolds. Related Links. Searching for New Antibiotics in the …See details»
Sfunga Therapeutics and Deerfield Management Announce …
Nov 8, 2023 – SF001, with QIDP and FDA Fast Track designations, in Phase 1 clinical development – NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Sfunga Therapeutics ("Sfunga"), a …See details»
'The Top Line': Turning down the toxicity of nature’s most …
Dec 8, 2023 This week on "The Top Line," Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., founder of antifungal startup Sfunga Therapeutics, to discuss the …See details»
Sfunga Therapeutics and Deerfield Management Announce …
Nov 9, 2023 – SF001, with QIDP and FDA Fast Track designations, in Phase 1 clinical development – NEW YORK, Nov. 8, 2023 /PRNewswire/ — Sfunga Therapeutics (“Sfunga”), a …See details»